Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Cash from Operations (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Cash from Operations data on record, last reported at 2152217.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 13.72% year-over-year to 2152217.0; the TTM value through Sep 2025 reached 8351664.0, down 20.92%, while the annual FY2024 figure was 6649281.0, 8.15% up from the prior year.
  • Cash from Operations reached 2152217.0 in Q3 2025 per COEP's latest filing, up from 2396742.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 59847.0 in Q3 2021 and bottomed at 4166890.0 in Q4 2021.
  • Average Cash from Operations over 5 years is 1535219.58, with a median of 1684470.0 recorded in 2023.
  • The widest YoY moves for Cash from Operations: up 79.66% in 2022, down 1626.42% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 4166890.0 in 2021, then soared by 79.66% to 847352.0 in 2022, then tumbled by 99.89% to 1693786.0 in 2023, then grew by 15.19% to 1436538.0 in 2024, then crashed by 49.82% to 2152217.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 2152217.0 in Q3 2025, 2396742.0 in Q2 2025, and 2366167.0 in Q1 2025.